NFE2L2 and colorectal carcinoma: By inhibiting AMPK, luteolin synergistically improves the antitumor efficacy of oxaliplatin in CRC (Jang et al., 2022), and sensitized oxaliplatin-resistant CRC cells to chemotherapy by suppressing the Nrf2 pathway (Chian et al., 2014).